Protect yourselves and scale in/out of positions correctly with risk management. In this market especially with penny stocks, you have to play defense, not offense. Follow for more alerts. Ticker: $SLRX Market Price: $.49 Shareholders Average: $1.01 Short Float: 1.55% Price Target: $1 Starter Position: $.50 Double Down: $.40 Final Position/Stop: $.35 Due Diligence: Cash and Cash Equivalents of $31.9M Sufficient to Fund Completion of Ongoing Clinical Trials for Lead Drug Candidate Seclidemstat. Added Five New Clinical Sites to Sarcoma Trial; 13 Active Sites Now Supporting Enrollment. Initial Ewing Sarcoma Combination Therapy Safety Lead-in Cohort Fully Enrolled, FET-Rearranged Sarcoma Patient Enrollment Continuing. December 29th Achieves Dosing Milestone in Ongoing Phase 1/2 Sarcoma Trial. Presenting at three events this upcoming week.
1
1
@Team_Bullish All this great news and the price keeps sinking. As if someone is trying to dump worthless shares and can’t find a sucker. Not to mention 1.3% ownership by insiders. Do I really need to post that chart again?
1
1 Like